Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Molecular markers guiding treatment approaches in bladder cancer

Daniel Petrylak, MD, Yale Cancer Center, New Haven, CT, reflects on key areas of unmet need in bladder cancer research, including the importance of molecular markers to guide personalized treatment approaches. Novel targeted therapies such as enfortumab vedotin, erdafitinib and sacitizumab govetican are being moved to earlier lines of treatment, highlighting the importance of patient stratification. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.